Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer

Background

There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).

The oncogenic impact of RNF2 on cell proliferation,invasion and migration through EMT on mammary carcinoma

Mammary carcinoma (MC) is one of most common malignancy in women, and ring finger protein 2 (RNF2) possesses various roles in vast human tumors. In MC tissues as well as in cell lines RNF2 exhibited high expression, had significant association with tumor size, lymph node status, TNM stage, patients’ poor survival, and promoted cell proliferation, colony formation, cell migration and invasion of MC cell lines which was mediated by downregulation of E-cadherin protein. These data reveal that RNF2 protein plays a vital role in the development of MC and may be a potential therapy target of MC.     

股骨上端松质骨拉伸应力松弛及蠕变的实验研究

目的研究正常国人新鲜尸体股骨上端松质骨的拉伸粘弹性力学性质,为临床提供生物力学参数。方法对股上端松质骨试样纵向进行拉伸应力松弛及蠕变实验。得到股骨上端松质骨纵向的应力松弛及蠕变数据和曲线。对实验数据进行归一化处理。结果分别用对数、指数一元回归分析的方法处理数据,得出了归一化应力松弛、归一化蠕变函数及曲线。结论股骨上端松质骨拉伸应力松弛7200s应力松弛量为0.422MPa,7200s蠕变量为0.784%。     

核因子红细胞2相关因子2在毒死蜱毒性机制中的作用

毒死蜱(chlorpyrifos,CPF)是一种广泛使用的有机磷农药,其对人类健康和生态系统的潜在风险已引起广泛关注。CPF主要通过抑制乙酰胆碱酯酶(AChE)发挥杀虫作用,但越来越多的研究表明,CPF的毒性作用远不止于此,也与氧化应激、炎症反应、 细胞死亡等多种生物学过程密切相关,因而可能导致神经退行性疾病、生殖发育障碍以及其他慢性健康问题。核因子红细胞2相关因子2(Nrf2)作为一种关键的抗氧化应激调节因子,具有显著的保护作用。本文旨在综述Nrf2在调节CPF诱导的氧化应激、神经毒性、细胞死亡和炎症反应中的作用机制,探讨其作为潜在治疗靶点的前景,以为开发新的CPF中毒治疗策略提供理论基础。     

术前NLR和PLR对上皮性卵巢癌患者预后的评估价值

目的:探讨术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)对上皮性卵巢癌患者预后的评估价值。方法:收集2005年11月至2012年12月在天津市中心妇产科医院初治且经手术治疗的153例卵巢良性肿瘤和206例上皮性卵巢癌患者的临床病理资料,比较术前NLR和PLR在卵巢良恶性肿瘤的区别,根据统计学方法选取NLR和PLR临界值,分析NLR和PLR与上皮性卵巢癌临床病理因素的关系。通过单因素及多因素分析评估术前NLR和PLR对患者术后生存的影响。结果:术前NLR和PLR水平在上皮性卵巢癌中明显高于卵巢良性肿瘤。选取NLR=2.62和PLR=173分别作为临界值。单因素分析结果显示,FIGO分期晚、中-低分化、腹水、脉管癌栓、CA125≥35、NLR≥2.62、PLR≥173是影响患者术后无病生存期(DFS)的危险因素(P0.05);FIGO分期晚、腹水、脉管癌栓、CA125≥35、PLR≥173是影响患者术后总生存期(OS)的危险因素(P0.05)。多因素分析显示,FIGO分期晚、NLR≥2.62、脉管癌栓是上皮性卵巢癌患者DFS的独立危险因素(P0.05)。结论:NLR和PLR方便测得且价格便宜,对卵巢癌的预后有一定的评估价值。     

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

BackgroundEpidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are currently recognized as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Clinically found patients with different EGFR mutational status have different prognosis.MethodsA retrospective cohort study was performed to explore the relationship between EGFR mutations and abundance with patient survival by using patient data from the Affiliated Cancer Hospital of Zhengzhou University between January 2013 and November 2016. All patients involved in the present study had sensitive EGFR mutations [either exon 19 deletion (DEL) or exon 21 L858R] and treated by EGFR-TKIs. They were followed up every three months until lost or dead. Mutation abundance was calculated as the copies of EGFR mutation divided by copies of EGFR locus, and the cut-off values for 19DEL and L858R were 4.9% and 9.5%, respectively.ResultsTotal of 236 patients were included, comprising 116 (49.2%) patients with 19DEL mutation and 120 (50.8%) patients with L858R mutation. The median follow-up duration was 23.2 months (95% CI: 14.9–26.7 months). Overall survival (OS) was significantly longer in patients with 19DEL mutation (20.9 months, 95% CI: 17.7–24.1 months versus 17.0 months, 95% CI: 14.4–19.6 months in patients with L858R; P=0.008) and in patients with high mutation abundance (20.9 months, 95% CI: 18.3–23.5 months versus 13.0 months, 95% CI: 10.3–15.7 months in patients with low mutation abundance; P<0.001). Multivariate Cox regression including age, performance status and tumor stage revealed that longer OS was independently associated with 19DEL mutation (HR: 0.48, 95% CI: 0.39–0.67, P=0.033) and high mutation abundance (HR: 0.62, 95% CI: 0.50–0.79, P=0.027).ConclusionsEGFR mutation types and abundance was associated with the patients’ survival which might be used to predict the efficacy of targeted therapy by EGFR-TKIs.     

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous cell lung carcinoma than in adenocarcinoma of the lung. Moreover, aberrant activation of PI3K/AKT/mTOR pathway is one of the mechanisms of acquired resistance to EGFR-TK inhibitors in patients with adenocarcinoma carrying EGFR activating mutations.     

Ogilvie’s syndrome: a case report

Objective Ogilvies syndrome (OS) is a rare condition in obstetrics but occurs most commonly after caesarean section. Mortality rates from OS can be as high as 36–50% when bowel perforation or ischemia develops which highlights the early recognition of this condition. Early diagnosis is therefore essential to prevent serious morbidity and mortality. Conclusion We, therefore report a case of OS after caesarean section in which early detection by senior clinicians resulted in successful management of the condition and an excellent outcome.     

硫化氢抑制骨肉瘤U2OS细胞的体外生长

【目的】 探讨硫化氢单独及与顺铂联用对骨肉瘤细胞生长的影响及其可能机制?【方法】 分别用0.2?0.4?0.6?0.8?1.0?2.0?3.0?4.0?5.0 mmol/L NaHS(硫化氢载体)单独或与20 mg/L顺铂共同作用骨肉瘤U2OS细胞24 h,CCK-8比色法法检测细胞存活率;分别用0.4及1.0 mmol/L NaHS作用骨肉瘤U2OS细胞24 h,1.0 mmol/L NaHS单独或与20 mg/L顺铂联用作用骨肉瘤U2OS细胞24 h,细胞单克隆形成法检测各组单克隆数;1.0 mmol/L NaHS与20 mg/L顺铂共同作用骨肉瘤U2OS细胞24 h,Western-Blot法检测Bcl-2?Bax?NFκB蛋白的表达?【结果】硫化氢对U2OS细胞生长的影响:0.2?0.4?0.6?0.8 mmol/L NaHS作用U2OS细胞24 h,细胞存活率与对照组比较,差异无统计学意义(P > 0.05); 1?2?3?4?5 mmol/L NaHS作用U2OS细胞24 h,细胞存活率分别为(90.01 ± 7.49)%?(88.00 ± 4.12)%?(87.26 ± 4.05)%?(85.40 ± 4.39)%和(82.99 ± 4.65)%,与对照组比较,能不同程度抑制U2OS细胞的生长(P 0.05)?NaHS与顺铂联用对骨肉瘤细胞的影响:分别用0.8?1?2?3?4?5 mmol/L NaHS联合20 mg/L顺铂共同作用U2OS细胞24 h,细胞存活率分别为(54.13 ± 4.03)%?(54.09 ± 1.13)%?(50.37 ± 4.56)%?(41.44 ± 3.95)%?(40.00 ± 4.34)%和(36.35 ± 3.90)%,与单用顺铂组(59.76 ± 3.15%)比较,存活率下降(P < 0.05)?NaHS+顺铂组细胞单克隆数为231.00 ± 13.52,与顺铂组(285.67 ± 11.59)比较,细胞单克隆数下降(P < 0.01); NaHS+顺铂组NFκB蛋白表达及Bcl-2/Bax蛋白表达比值较顺铂组下降?【结论】 1 mmol/L浓度以上的NaHS能抑制骨肉瘤细胞的生长,0.8 mol/L浓度以上的NaHS通过减少NFκB入核,增加细胞的凋亡,从而增强顺铂对骨肉瘤细胞的抑制作用?